<Anchor> During the
night, a US pharmaceutical company called Modenara revealed that the preventive effect of the Corona 19 vaccine they are developing was 94.5%.
Although it is an intermediate clinical trial result, it is expected that a vaccine can be released within this year with Pfizer, raising expectations for the conquest of COVID-19.
Reporter Kim A-young reports.
<Reporter>
US pharmaceutical company Modena analyzed the prevention rate of vaccine candidates under development with the US National Allergy-Infection Research Institute, and said it was 94.5%.
This is the result of a Phase 3 test with 30,000 test participants in 89 cities in the United States.
Modena said that the vaccine could be a game-changing game changer in the corona phase.
[Stephane Bangsell/Modena CEO: This is a very important milestone in the fight against the global pandemic.
This is because our vaccine, mRNA-1273, has shown that it can prevent COVID-19, including people with severe diseases and illnesses.]
Anthony Pouch, head of the National Allergy-Infection Research Institute, also responded positively, saying, "This is very good news". .
The prevention rate revealed by Modena is similar to the measles vaccine, which is said to have the highest prevention rate among existing vaccines.
The U.S. government has already signed a contract worth 1.7 trillion won with Modena to purchase the vaccine, and it is expected that there will be an application for emergency use approval within this month.
Earlier on the 9th, an interim study was announced that the vaccine developed by Pfizer, a US pharmaceutical company, has a 90% preventive effect.
Pfizer vaccines should be stored at cryogenic temperatures above -70 degrees Celsius, while modder vaccines can be stored in a general medical refrigerator for up to 30 days.